Trials Sponsors Conditions Drugs Pricing

Conditions

ICI-refractory Non-Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

Safety and adverse events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Through study completion; an average of 1 year

Study Arms (1)

Phase II biomarker study of SAR445877

EXPERIMENTAL

Will receive SAR445877 by vein over about 60 minutes every 2 weeks, on Day 1 of each 14-day cycle.

Drug: SAR445877

Interventions

SAR445877Drug

Given by IV

Phase II biomarker study of SAR445877

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs.
Participants who are pregnant or breastfeeding.

Sponsors & Collaborators

Sanofi
Industrycollaborator
M.D. Anderson Cancer Center
Otherlead

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Natalie Vokes, MDCONTACT713-303-6890 nvokes@mdanderson.org

Natalie Vokes, MDPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

Natalie Vokes, MD
M.D. Anderson Cancer Center
PRINCIPAL INVESTIGATOR

Central Study Contacts

Natalie Vokes, MD

CONTACT

713-303-6890 nvokes@mdanderson.org

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 19, 2025

First Posted

August 21, 2025

Study Start

November 6, 2025

Actual (reported)

Primary Completion

February 1, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Phase II biomarker study of SAR445877

Interventions

Eligibility Criteria

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Phase II biomarker study of SAR445877

Interventions

Eligibility Criteria

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations